TY - JOUR
T1 - The duke afm program intensive induction chemotherapy for metastatic breast cancer
AU - Jones, Roy B.
AU - Shpall, Elizabeth J.
AU - Shogan, Jeffrey
AU - Affronti, Mary Lou
AU - Coniglio, David
AU - Hart, Lowell
AU - Halperin, Edward
AU - Dirk Iglehart, J.
AU - Moore, Joseph
AU - Gockerman, Jon
AU - Bast, Robert C.
AU - Peters, William P.
PY - 1990/8/1
Y1 - 1990/8/1
N2 - Forty‐five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5‐fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high‐dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.
AB - Forty‐five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5‐fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high‐dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.
UR - http://www.scopus.com/inward/record.url?scp=0025303591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025303591&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19900801)66:3<431::AID-CNCR2820660305>3.0.CO;2-X
DO - 10.1002/1097-0142(19900801)66:3<431::AID-CNCR2820660305>3.0.CO;2-X
M3 - Article
C2 - 2364358
AN - SCOPUS:0025303591
SN - 0008-543X
VL - 66
SP - 431
EP - 436
JO - Cancer
JF - Cancer
IS - 3
ER -